Clinical Trial Update: Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load [Phase 2]

View source ↗

Summary

A Phase 2 trial of durvalumab plus olaparib for prostate cancer in men predicted to have a high neoantigen load was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: University of Washington | Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-08-11